摘要
目的：探讨得舒特联合黛力新、美常安治疗肠易激综合征（IBS）的疗效。方法：收集2012年1月-2014年12月在我院诊断为符合IBS患者457例,随机分为黛力新联合得舒特、美常安（观察组）患者154例,得舒特联合美常安组（对照1组）患者151例及黛力新联合得舒特组（对照2组）患者152例;治疗2周后对疗效进行评估。结果：观察组的疗效优于对照1组及对照2组,差异均具有统计学意义（P〈0.05）,对照1组和对照2组的疗效差别不大（P〉0.05）。治疗后观察组临床症状与对照组的差异有统计学意义（P〈0.05）。结论：得舒特联合黛力新、美常安治疗肠易激综合征比仅其中两者联用更为有效。
Objective To investigate and analysis the curative effect of Deanxit unite Dicetel and Medilac-S to treat irritable bowel syndrome. Methods We collected 427 cases of patients for irritable bowel syndrome from January 2013 to December 2014 in our hospital,were randomly divided into three groups. The treatment group（n=154）：Deanxit unite Dicetel and Medilac-S;the control group 1 （n=151）： Dicetel unite Medilac-S; the control group 2 （n=152）： Deanxit unite Dicetel. after 2 weeks of treatment, evaluating the therapeutic effect. Results The efficacy of the treatment group is higher than the other two in the control group,（P〈0.05）, control group 1 and control group 2 have little difference in efficacy. There are differences in clinical symptoms between treatment group and control group （P〈0.05）. Conclusion Dicetel unite Deanxit and Medilac-S for treating diarrhea irritable bowel syndrome is more effective than the combination of two of them.
出处
《北方药学》
2015年第6期111-112,共2页
Journal of North Pharmacy
